Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.2.13 (
aldolase
)
3,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We examined the in vivo and in vitro effects of soman on
aldolase
activity. Male rats were killed at 4, 6, 9 and 12.5 min after subcutaneous (s.c.) administration of 90 micrograms/kg soman. At 4 min after treatment,
aldolase
activity was inhibited 55-90% compared to control in cerebral cortex, brainstem, mid-brain and cerebellum; and up to 50% of control in diaphragm and muscle. By 12.5 min,
aldolase
activity in all areas had returned to control levels except in the diaphragm, which still exhibited 36% inhibition. In vitro activity of rabbit muscle
aldolase
was not inhibited by 10(-3) M soman. In contrast, diisopropylfluorophosphonate (
DFP
, 10(-3)-10(-2) M) acted as a competitive inhibitor of
aldolase
activity in vitro. The results suggest that in vivo, soman effects on
aldolase
activity are transitory. Any long-lasting effects of soman on
aldolase
activity may occur only in the periphery, and not in the central nervous system.
...
PMID:The effects of soman, in vivo and in vitro, on aldolase activity. 407 59